Everence Capital Management Inc. Invests $3.45 Million in Amgen Inc. (NASDAQ:AMGN)
Everence Capital Management Inc. acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the 1st quarter, HoldingsChannel.com reports. The institutional investor acquired 13,878 shares of the medical research company’s stock, valued at approximately $3,453,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of AMGN. Advisory Alpha LLC acquired a new stake in shares of Amgen during the third quarter worth $25,000. Fort Pitt Capital Group LLC acquired a new stake in Amgen in the fourth quarter worth $28,000. Norway Savings Bank acquired a new stake in Amgen in the fourth quarter worth $29,000. Crescent Capital Consulting LLC acquired a new stake in Amgen in the fourth quarter worth $34,000. Finally, Kinloch Capital LLC acquired a new stake in Amgen in the fourth quarter worth $40,000. Institutional investors own 75.23% of the company’s stock.
A number of research analysts have recently issued reports on AMGN shares. Barclays reduced their price objective on shares of Amgen from $242.00 to $230.00 and set an “equal weight” rating for the company in a report on Thursday, March 11th. The Goldman Sachs Group set a $277.00 price objective on shares of Amgen and gave the company a “buy” rating in a report on Thursday, March 4th. Cantor Fitzgerald lifted their price objective on shares of Amgen from $280.00 to $295.00 and gave the company an “overweight” rating in a report on Wednesday, February 3rd. SVB Leerink lifted their price objective on shares of Amgen from $252.00 to $260.00 and gave the company a “market perform” rating in a report on Monday, March 8th. Finally, Morgan Stanley lifted their price objective on shares of Amgen from $277.00 to $279.00 and gave the company an “overweight” rating in a report on Thursday, March 11th. Ten analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Amgen presently has a consensus rating of “Buy” and a consensus target price of $258.57.
AMGN stock traded down $0.47 during mid-day trading on Thursday, hitting $247.65. The company had a trading volume of 37,901 shares, compared to its average volume of 2,729,896. The firm has a market cap of $143.03 billion, a PE ratio of 20.00, a price-to-earnings-growth ratio of 1.90 and a beta of 0.76. The company has a debt-to-equity ratio of 3.12, a quick ratio of 1.88 and a current ratio of 2.28. Amgen Inc. has a 12 month low of $207.34 and a 12 month high of $276.69. The stock’s fifty day moving average price is $237.64 and its two-hundred day moving average price is $235.35.
Amgen (NASDAQ:AMGN) last posted its earnings results on Monday, February 1st. The medical research company reported $3.81 earnings per share for the quarter, topping the consensus estimate of $3.39 by $0.42. The firm had revenue of $6.63 billion during the quarter, compared to the consensus estimate of $6.57 billion. Amgen had a net margin of 29.42% and a return on equity of 95.55%. The company’s revenue was up 7.1% on a year-over-year basis. During the same quarter last year, the company earned $3.64 earnings per share. Equities analysts anticipate that Amgen Inc. will post 16.15 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 8th. Stockholders of record on Monday, May 17th will be paid a $1.76 dividend. The ex-dividend date is Friday, May 14th. This represents a $7.04 annualized dividend and a dividend yield of 2.84%. Amgen’s payout ratio is 47.50%.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with BehÃ§et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
See Also: What is a trade deficit?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.